Assertio-Garda deal analysis: what the Rolvedon-focused takeover means for specialty pharma investors
Find out why Assertio is being sold to Garda Therapeutics and what the Rolvedon-focused deal means for specialty pharma strategy.
Pharma & Biotech
Pharma & Biotech
Can TAE Life Sciences turn BNCT into a credible radio-immunotherapy platform for hard-to-treat cancers?
TAE Life Sciences’ BNCT study showed stronger boron delivery and immune effects in preclinical models. Read what this could change for oncology.
Pharma & Biotech
Why Corcept Therapeutics now faces a bigger execution test after Lifyorli’s ROSELLA success
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Pharma & Biotech
What Eric J. Daniels’ appointment means for Plus Therapeutics and its CNS oncology pipeline
Plus Therapeutics has named Eric J. Daniels as Chief Development Officer. Read what this means for REYOBIQ, CNS oncology execution, and pipeline risk.
Pharma & Biotech
Why Vivatides Therapeutics’ $54m Series A matters for extrahepatic RNA therapeutics
Vivatides Therapeutics raised $54 million to advance extrahepatic RNA therapeutics. Read why this platform bet could reshape RNA drug development.
Pharma & Biotech
Can REYOBIQ improve Plus Therapeutics’ path in pediatric high-grade glioma and ependymoma?
Plus Therapeutics won orphan drug designation for REYOBIQ in pediatric malignant gliomas. Read what it changes for CNS cancer development.
Pharma & Biotech
Why DualityBio’s China filing for trastuzumab pamirtecan matters in the HER2 breast cancer ADC race
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.
Pharma & Biotech
Can zemprocitinib help Lynk Pharmaceuticals break into China’s crowded atopic dermatitis market?
Lynk Pharmaceuticals won NMPA acceptance for zemprocitinib in atopic dermatitis. Read what this filing changes, and what risks still remain.
Pharma & Biotech
Why MetaVia’s higher-dose titration strategy could matter more than the first-patient milestone itself
MetaVia has started higher-dose testing for DA-1726 in obesity. Read what this means for tolerability, competition, and the next clinical milestone.
Pharma & Biotech
Whitehawk Therapeutics sharpens HWK-016 case as MUC16 emerges as a stronger ADC target in gynecologic cancers
Whitehawk Therapeutics says new MUC16 data support HWK-016 in gynecologic cancers. Read what this could change for ADC development.